Published in Obesity and Diabetes Week, March 15th, 2004
Palatin reported total revenues for the second quarter of fiscal year ending June 30, 2004, of $291,354 and a net loss of $4.6 million or $0.10 per share. In the second quarter of fiscal year ended June 30, 2003, total revenues were $233,505 and net loss was $4.5 million, or $0.18 per share.
The slight increase in net loss for the quarter ended December 31, 2003, compared to December 31, 2002, was mainly attributable to increases in operating expenses related to ongoing clinical trials and advancement of PT-141, the company's product under investigation for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week